Prostate Cancer Studies STUDIES CURRENTLY RECRUITING ARN-509 - SPARTAN Study Phase III study comparing ARN-509 (pill) to placebo for patients with non-metastatic prostate cancer Recruiting Galeterone - TOK ARMOR 2 study
2 part Phase II study of galeterone -TOK (pill) for patients with metastatic prostate cancer pre and post-chemotherapy Recruiting Genentec GDC + Zytiga Phase II study of GDC + Zytiga, versus Zytiga alone for patients with advanced prostate cancer previously treated with chemotherapy Recruiting OGX-011 (Custersin) + Jevtana Phase III study of Jevtana +/- Custersin second line chemotherapy for patients with metastatic prostate cancer Recruiting Prolia (denosunab) Phase III study to evaluate Prolia for patients with prostate cancer taking hormones Recruiting Prostvac (vaccine) Phase III study vaccination study for patients with advanced prostate cancer who have not yet received treatment with chemotherapy and have no symptoms or minimal symptoms Recruiting
Provenge PROCEED study (vaccine) Registry study to collect long term safety data for patients receiving Provenge vaccine Recruiting Provenge PROCEED sub - study Immune response study (additional blood samples collected) for patients participating in PROCEED study Recruiting
PSMA ADC Phase II study of PSMA ADC (target chemotherapy) in patients with metastatic prostate cancer who have failed chemotherapy Recruiting VT-464-CL-001 (testosterone inhibitor) Phase I/II study to evaluate the safety of the study drug VT-464 (pill) and how it affects patients with prostate cancer Recruiting XL184 (Cabozantinib) Phase II study comparing XL184 (Cabozantinib) (pill) vs. Prednisone only for patients who have failed Zytiga (abiraterone) or Xtandi (MDV3100) Recruiting Xtandi (MDV 3100) - STRIVE Phase II study comparing Xtandi to standard of care Casodex for patients with Prostate cancer Recruiting Zytiga - Rising PSA IMAAGEN study Phase III study of Zytiga plus prednisone for patients with rising PSA prostate cancer who are receiving hormone therapy Recruiting Androgen deprivation vs. Radiotherapy Phase III study comparing androgen deprivation prior with pelvic lymph node dissection vs. radiotherapy only Recruiting Taxotere Phase III study to evaluate the addition of Taxotere prior to surgery to improve outcome for patients with newly diagnosed high risk prostate cancer Recruiting
Taxotere +/- GM-CSF Phase II study of intermittent Taxotere vs. intermittent Taxotere with GM-CSF Recruiting STUDIES ACTIVE, CLOSED TO ENROLLMENT
TAK-700 (Orteronel) Pre-chemotherapy Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy Closed to enrollment – active follow-up TAK-700 (Orteronel) Post-chemotherapy Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer previously treated with chemotherapy Closed to enrollment – active follow-up TAK-700 (Orteronel) Phase II Open-label study of oral TAK-700 plus prednisone, evaluating the effects on the heart for patients with advanced prostate cancer Closed to enrollment – active follow-up
TAK-700 (Orteronel) Phase II Open-label study of oral TAK-700 plus prednisone, evaluating dosing options for patients with advanced prostate cancer Closed to enrollment – active follow- up Zytiga Cougar 302 study Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy Closed to enrollment – active follow-up Zytiga + Provenge Open-label Phase II study of Provenge with concurrent or sequential Zytiga. Closed to enrollment – active follow-up
PRIOR STUDIES - CLOSED Zytiga Cougar 301 study Phase III study of oral Zytiga plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed Zytiga EAP study EAP oral Zytiga plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed
MDV3100 EAP study
EAP oral MDV3100 for patients with advanced prostate cancer who have already received chemotherapy Closed TroVax Phase II study to evaluate the addition of TroVax vaccination to standard Taxotere chemotherapy for patients with advanced prostate cancer Closed OGX-011 (Custersin) Phase III study of OGX-011 (Custersin) added to Taxotere for second line treatment evaluation of pain palliation Closed Eligard +/- Taxotere - Rising PSA A Phase III study Eligard +/- Taxotere for patients with Rising PSA Closed
The knowledge of applying medicinal herbs in disease therapy has a long-standing traditionBuilding on that tradition, while implementing the latest scientific research findings, Belupo hasdeveloped the Favora product line, intended as the support therapy in treatment of acute andchronic diseases, and providing dietetic supplements of high nutritional value. AKTIVIN® – H1 capsule contains
ORAL ANTICOAGULATION WITH WARFARIN Warfarin orders for inpatients must be written daily (i.e., no standing University of California San Francisco Medical Center orders) If no dose is intended or the dose is to be withheld, write an order Comprehensive Hemostasis and Antithrombotic Service (CHAS) to this effect. NOTE : These recommendations should be used in conjunction wit
Prostate Cancer Studies 
STUDIES ACTIVE, CLOSED TO ENROLLMENT 
MDV3100 EAP study